Exonate Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $1.9M

  • Investors
  • 19

Exonate General Information

Description

Developer of a biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. The company offers program molecules, for wet age-related macular degeneration (wet AMD), which act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological vascular endothelial growth factor without inhibiting beneficial, non-pathological vascular endothelial growth factor (VEGF), helping doctors to focus on developing novel therapies for wet age-related macular degeneration.

Contact Information

Website
www.exonate.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • WTL Moorfield Road, Duxford
  • Cambridgeshire
  • Cambridge CB22 4PS
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • WTL Moorfield Road, Duxford
  • Cambridgeshire
  • Cambridge CB22 4PS
  • England, United Kingdom
+44 01223

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exonate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 03-Jan-2019 $1.9M Completed Clinical Trials - Phase 2
6. Later Stage VC 12-Sep-2018 Completed Clinical Trials - Phase 1
5. Grant 06-Feb-2017 Completed Clinical Trials - Phase 1
4. Early Stage VC 01-Dec-2016 Completed Clinical Trials - Phase 1
3. Early Stage VC 05-Oct-2015 Completed Clinical Trials - Phase 1
2. Seed Round 01-Mar-2014 $651K $651K Completed Clinical Trials - Phase 1
1. University Spin-Out 01-Jan-2013 Completed Startup
To view Exonate’s complete valuation and funding history, request access »

Exonate Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 14,141 $0.012877 $72.11 $72.11 1x $72.11 17.79%
Ordinary 7,860 $0.012877 $64.39 $64.39 1x $64.39 9.89%
To view Exonate’s complete cap table history, request access »

Exonate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and t
Drug Discovery
Cambridge, United Kingdom
15 As of 2025

London, United Kingdom
 

Charlottesville, VA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exonate Competitors (28)

One of Exonate’s 28 competitors is Oxular, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxular Formerly VC-backed London, United Kingdom
TearSolutions Venture Capital-Backed Charlottesville, VA
Allegro Ophthalmics Venture Capital-Backed San Juan Capistrano, CA
Kala Bio Formerly VC-backed Arlington, MA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 28 competitors. Get the full list »

Exonate Patents

  • 46

    Total Documents Applications and Grants

  • Total Patents Families

  • 35

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Exonate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3183466-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Pending 14-Jul-2020
AU-2021309894-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Pending 14-Jul-2020
US-20220411412-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Active 14-Jul-2020
EP-4182311-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Active 14-Jul-2020
GB-202010829-D0 Compounds for treatment of neovascular diseases Inactive 14-Jul-2020 C07D405/14
To view Exonate’s complete patent history, request access »

Exonate Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exonate Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
EMV Capital Venture Capital Minority
Stoic Venture Capital Venture Capital Minority
University of Bristol Endowment Limited Partner Minority
R42 Group Venture Capital Minority
Wellcome Trust Limited Partner
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial

Exonate FAQs

  • When was Exonate founded?

    Exonate was founded in 2013.

  • Where is Exonate headquartered?

    Exonate is headquartered in Cambridge, United Kingdom.

  • What is the size of Exonate?

    Exonate has 15 total employees.

  • What industry is Exonate in?

    Exonate’s primary industry is Drug Discovery.

  • Is Exonate a private or public company?

    Exonate is a Private company.

  • What is Exonate’s current revenue?

    The current revenue for Exonate is .

  • How much funding has Exonate raised over time?

    Exonate has raised $7.74M.

  • Who are Exonate’s investors?

    EMV Capital, Stoic Venture Capital, University of Bristol Endowment, R42 Group, and Wellcome Trust are 5 of 19 investors who have invested in Exonate.

  • Who are Exonate’s competitors?

    Oxular, TearSolutions, Allegro Ophthalmics, Kala Bio, and Alnylam Pharmaceuticals are some of the 28 competitors of Exonate.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »